Mittie Doyle, Chief Officer of Avalo Therapeutics AVTX, has filed 0 purchases and 12 sales on the open market. Over the past 12 months that comes to a net sale of $2.8M. The latest trade was on 06/23.

MD

MD

Mittie Doyle

Chief Medical Officer

Company

Avalo Therapeutics AVTX

First filing

23/08/09

Trades

43 trades

Buys / sales

0 / 12

12-month net buying

−$2.8M

Last trade

06/23

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	06/23	06/25	1,450 sh	$18.00	$26,100	−2.7%
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	05/28	06/01	679 sh	$16.00	$10,864	−1.4%
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	05/15	05/19	3,000 sh	$18.76	$56,280	−45.3%
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	05/05–05/06	05/07	108,234 sh6 trades	$20.61avg.	$2,230,690.13	−96.8%
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	04/06	04/08	3,970 sh	$18.01	$71,499.7	−52.3%
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	04/01	04/03	679 sh	$16.00	$10,864	−15.8%
Avalo TherapeuticsAVTX	Open-market sale10b5-1 plan	03/16	03/18	25,492 sh	$16.15	$411,695.8	−87.6%